患者血液受累情况下莫加莫拉单抗对健康相关生活质量的影响。 - Suppr

Health-related quality of life effect of mogamulizumab by patient blood involvement.

作者信息

Zinzani Pier Luigi, Ortiz-Romero Pablo, Lima Margarida, Huen Auris O

机构信息

Institute of Hematology "Seràgnoli", University of Bologna, Bologna, Italy.

Department of Dermatology, University Complutense, Hospital 12 de Octubre, Medical School, Institute i+12, Madrid, Spain.

出版信息

Eur J Cancer. 2021 Oct;156 Suppl 1:S65-S66. doi: 10.1016/S0959-8049(21)00749-8.

DOI:10.1016/S0959-8049(21)00749-8

PMID:34649667

Abstract

摘要

相似文献

Eur J Cancer. 2021 Oct;156 Suppl 1:S65-S66. doi: 10.1016/S0959-8049(21)00749-8.

Efficacy of mogamulizumab in mycosis fungoides by patient blood involvement and time to response analysis in mycosis fungoides and Sézary syndrome: a post hoc analysis of the MAVORIC study.

Eur J Cancer. 2021 Oct;156 Suppl 1:S47-S48. doi: 10.1016/S0959-8049(21)00714-0.

Spotlight on Mogamulizumab-Kpkc for Use in Adults with Relapsed or Refractory Mycosis Fungoides or Sézary Syndrome: Efficacy, Safety, and Patient Selection.

Drug Des Devel Ther. 2020 Sep 16;14:3747-3754. doi: 10.2147/DDDT.S185896. eCollection 2020.

Patient characteristics of long-term responders to mogamulizumab: results from the MAVORIC study.

Eur J Cancer. 2021 Oct;156 Suppl 1:S48-S49. doi: 10.1016/S0959-8049(21)00715-2.

Characterization and outcomes in patients with mogamulizumab-associated skin reactions in the MAVORIC trial.

Eur J Cancer. 2021 Oct;156 Suppl 1:S46. doi: 10.1016/S0959-8049(21)00712-7.

Understanding relative survival outcomes for patients with cutaneous T-cell lymphoma (CTCL) subtypes mycosis fungoides and Sézary syndrome treated with mogamulizumab or vorinostat: combining Australian real-world evidence and MAVORIC phase 3 trial data.

Eur J Cancer. 2021 Oct;156 Suppl 1:S18. doi: 10.1016/S0959-8049(21)00659-6.

Mogamulizumab in the treatment of advanced mycosis fungoides and Sézary syndrome: safety and efficacy.

Expert Rev Anticancer Ther. 2020 Jun;20(6):447-452. doi: 10.1080/14737140.2020.1760096. Epub 2020 Apr 28.

Efficacy and safety of mogamulizumab by patient baseline blood tumour burden: a post hoc analysis of the MAVORIC trial.

J Eur Acad Dermatol Venereol. 2021 Nov;35(11):2225-2238. doi: 10.1111/jdv.17523. Epub 2021 Aug 20.

Successful Treatment of Erythrodermic Mycosis Fungoides with Mogamulizumab Followed by Etoposide Monotherapy.

Case Rep Oncol. 2018 Jan 16;11(1):29-32. doi: 10.1159/000486278. eCollection 2018 Jan-Apr.

Cutaneous T-Cell Lymphoma: Optimizing Care in Patients Receiving Anti-CCR4 Monoclonal Antibody Mogamulizumab.

Clin J Oncol Nurs. 2019 Aug 1;23(4):E73-E80. doi: 10.1188/19.CJON.E73-E80.

引用本文的文献

J Eur Acad Dermatol Venereol. 2025 Apr;39(4):833-845. doi: 10.1111/jdv.20357. Epub 2024 Sep 24.

Quality of Life in Cutaneous T-cell Lymphoma Patients Receiving Mogamulizumab: Important Factors to Consider.

Cancers (Basel). 2022 Dec 21;15(1):32. doi: 10.3390/cancers15010032.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Health-related quality of life effect of mogamulizumab by patient blood involvement.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

Health-related quality of life effect of mogamulizumab by patient blood involvement.

作者信息

机构信息

出版信息

相似文献

引用本文的文献